Trials / Completed
CompletedNCT01614912
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 284 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SM-13496 | 40 or 80 mg once daily orally |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2012-06-08
- Last updated
- 2022-04-12
- Results posted
- 2018-10-19
Locations
4 sites across 4 countries: Japan, Malaysia, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01614912. Inclusion in this directory is not an endorsement.